The World Allergy Organization journal
Nov 24, 2020
BACKGROUND: Omalizumab has demonstrated efficacy as an add-on therapy in Chinese patients with moderate-to-severe allergic asthma. This analysis assessed the potential predictors for the efficacy of omalizumab in these patients.